1
|
Göktuna SI, Canli O, Bollrath J, Fingerle AA, Horst D, Diamanti MA, Pallangyo C, Bennecke M, Nebelsiek T, Mankan AK, Lang R, Artis D, Hu Y, Patzelt T, Ruland J, Kirchner T, Taketo MM, Chariot A, Arkan MC, Greten FR. IKKα Promotes Intestinal Tumorigenesis by Limiting Recruitment of M1-like Polarized Myeloid Cells. Cell Rep 2022; 38:110471. [PMID: 35235803 DOI: 10.1016/j.celrep.2022.110471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
3
|
Göktuna SI, Canli O, Bollrath J, Fingerle AA, Horst D, Diamanti MA, Pallangyo C, Bennecke M, Nebelsiek T, Mankan AK, Lang R, Artis D, Hu Y, Patzelt T, Ruland J, Kirchner T, Taketo MM, Chariot A, Arkan MC, Greten FR. IKKα promotes intestinal tumorigenesis by limiting recruitment of M1-like polarized myeloid cells. Cell Rep 2014; 7:1914-25. [PMID: 24882009 DOI: 10.1016/j.celrep.2014.05.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 04/16/2014] [Accepted: 05/02/2014] [Indexed: 12/18/2022] Open
Abstract
The recruitment of immune cells into solid tumors is an essential prerequisite of tumor development. Depending on the prevailing polarization profile of these infiltrating leucocytes, tumorigenesis is either promoted or blocked. Here, we identify IκB kinase α (IKKα) as a central regulator of a tumoricidal microenvironment during intestinal carcinogenesis. Mice deficient in IKKα kinase activity are largely protected from intestinal tumor development that is dependent on the enhanced recruitment of interferon γ (IFNγ)-expressing M1-like myeloid cells. In IKKα mutant mice, M1-like polarization is not controlled in a cell-autonomous manner but, rather, depends on the interplay of both IKKα mutant tumor epithelia and immune cells. Because therapies aiming at the tumor microenvironment rather than directly at the mutated cancer cell may circumvent resistance development, we suggest IKKα as a promising target for colorectal cancer (CRC) therapy.
Collapse
Affiliation(s)
- Serkan I Göktuna
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Unit of Signal Transduction (GIGA-ST), GIGA-R, University of Liege and WELBIO, CHU, Sart-Tilman, 4000 Liege, Belgium
| | - Ozge Canli
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt am Main, Germany
| | - Julia Bollrath
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Alexander A Fingerle
- Department of Radiology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - David Horst
- Institute of Pathology, Ludwig-Maximilian-University, 80337 Munich, Germany
| | - Michaela A Diamanti
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt am Main, Germany
| | - Charles Pallangyo
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt am Main, Germany
| | - Moritz Bennecke
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Tim Nebelsiek
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Arun K Mankan
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Roland Lang
- Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen, 91054 Erlangen, Germany
| | - David Artis
- Department of Microbiology and Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yinling Hu
- Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21701, USA
| | - Thomas Patzelt
- Department of Clinical Chemistry, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Jürgen Ruland
- Department of Clinical Chemistry, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Thomas Kirchner
- Institute of Pathology, Ludwig-Maximilian-University, 80337 Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - M Mark Taketo
- Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
| | - Alain Chariot
- Unit of Signal Transduction (GIGA-ST), GIGA-R, University of Liege and WELBIO, CHU, Sart-Tilman, 4000 Liege, Belgium
| | - Melek C Arkan
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | - Florian R Greten
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt am Main, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
| |
Collapse
|
4
|
Shostak K, Patrascu F, Göktuna SI, Close P, Borgs L, Nguyen L, Olivier F, Rammal A, Brinkhaus H, Bentires-Alj M, Marine JC, Chariot A. MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation. Cell Death Differ 2014; 21:811-24. [PMID: 24488098 DOI: 10.1038/cdd.2014.2] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 12/18/2013] [Accepted: 12/23/2013] [Indexed: 12/25/2022] Open
Abstract
Restoration of p53 tumor suppressor function through inhibition of its interaction and/or enzymatic activity of its E3 ligase, MDM2, is a promising therapeutic approach to treat cancer. However, because the MDM2 targetome extends beyond p53, MDM2 inhibition may also cause unwanted activation of oncogenic pathways. Accordingly, we identified the microtubule-associated HPIP, a positive regulator of oncogenic AKT signaling, as a novel MDM2 substrate. MDM2-dependent HPIP degradation occurs in breast cancer cells on its phosphorylation by the estrogen-activated kinase TBK1. Importantly, decreasing Mdm2 gene dosage in mouse mammary epithelial cells potentiates estrogen-dependent AKT activation owing to HPIP stabilization. In addition, we identified HPIP as a novel p53 transcriptional target, and pharmacological inhibition of MDM2 causes p53-dependent increase in HPIP transcription and also prevents HPIP degradation by turning off TBK1 activity. Our data indicate that p53 reactivation through MDM2 inhibition may result in ectopic AKT oncogenic activity by maintaining HPIP protein levels.
Collapse
Affiliation(s)
- K Shostak
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium
| | - F Patrascu
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium
| | - S I Göktuna
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium
| | - P Close
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium
| | - L Borgs
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Developmental Neurobiology Unit, GIGA-Neurosciences, GIGA-R, University of Liège, Liège, Belgium
| | - L Nguyen
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Developmental Neurobiology Unit, GIGA-Neurosciences, GIGA-R, University of Liège, Liège, Belgium [3] Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wallonia, Belgium
| | - F Olivier
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Animal Facility, University of Liege, CHU, Sart-Tilman, Liège 4000, Belgium
| | - A Rammal
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium
| | - H Brinkhaus
- Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland
| | - M Bentires-Alj
- Mechanisms of Cancer, Friedrich Miescher Institute for Biomedical Research (FMI), Basel, Switzerland
| | - J-C Marine
- 1] Center for Human Genetics, KU Leuven, Leuven, Belgium [2] Center for the biology of disease, VIB, KU Leuven, Leuven, Belgium
| | - A Chariot
- 1] Interdisciplinary Cluster for Applied Genoproteomics, GIGA-Research, University of Liège, Liège, Belgium [2] Unit of Medical Chemistry, GIGA-Signal Transduction, GIGA-R, University of Liège, Liège, Belgium [3] Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wallonia, Belgium
| |
Collapse
|
5
|
Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, Rupec RA, Gerhard M, Schmid R, Barker N, Clevers H, Lang R, Neumann J, Kirchner T, Taketo MM, van den Brink GR, Sansom OJ, Arkan MC, Greten FR. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013; 152:25-38. [PMID: 23273993 DOI: 10.1016/j.cell.2012.12.012] [Citation(s) in RCA: 774] [Impact Index Per Article: 70.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Revised: 06/12/2012] [Accepted: 12/04/2012] [Indexed: 02/06/2023]
Abstract
Cell-type plasticity within a tumor has recently been suggested to cause a bidirectional conversion between tumor-initiating stem cells and nonstem cells triggered by an inflammatory stroma. NF-κB represents a key transcription factor within the inflammatory tumor microenvironment. However, NF-κB's function in tumor-initiating cells has not been examined yet. Using a genetic model of intestinal epithelial cell (IEC)-restricted constitutive Wnt-activation, which comprises the most common event in the initiation of colon cancer, we demonstrate that NF-κB modulates Wnt signaling and show that IEC-specific ablation of RelA/p65 retards crypt stem cell expansion. In contrast, elevated NF-κB signaling enhances Wnt activation and induces dedifferentiation of nonstem cells that acquire tumor-initiating capacity. Thus, our data support the concept of bidirectional conversion and highlight the importance of inflammatory signaling for dedifferentiation and generation of tumor-initiating cells in vivo.
Collapse
Affiliation(s)
- Sarah Schwitalla
- Institute of Molecular Immunology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007; 130:918-31. [PMID: 17803913 PMCID: PMC2134986 DOI: 10.1016/j.cell.2007.07.009] [Citation(s) in RCA: 507] [Impact Index Per Article: 29.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2006] [Revised: 05/16/2007] [Accepted: 07/06/2007] [Indexed: 01/03/2023]
Abstract
IKKbeta-dependent NF-kappaB activation plays a key role in innate immunity and inflammation, and inhibition of IKKbeta has been considered as a likely anti-inflammatory therapy. Surprisingly, however, mice with a targeted IKKbeta deletion in myeloid cells are more susceptible to endotoxin-induced shock than control mice. Increased endotoxin susceptibility is associated with elevated plasma IL-1beta as a result of increased pro-IL-1beta processing, which was also seen upon bacterial infection. In macrophages enhanced pro-IL-1beta processing depends on caspase-1, whose activation is inhibited by NF-kappaB-dependent gene products. In neutrophils, however, IL-1beta secretion is caspase-1 independent and depends on serine proteases, whose activity is also inhibited by NF-kappaB gene products. Prolonged pharmacologic inhibition of IKKbeta also augments IL-1beta secretion upon endotoxin challenge. These results unravel an unanticipated role for IKKbeta-dependent NF-kappaB signaling in the negative control of IL-1beta production and highlight potential complications of long-term IKKbeta inhibition.
Collapse
Affiliation(s)
- Florian R Greten
- Second Department of Medicine, Klinikum rechts der Isar, Technical University Munich, 81675 Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|